SavedAdd your journal

Journals / Bozok Tıp Dergisi / 2019 / Cilt: 9 - Sayı: 2

Presentations and Outcomes of Patients with Residual Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma

TİROİDEKTOMİ SONRASI REZİDÜ DOKU TESPİT EDİLEN DİFERANSİYE TİROİD KARSİNOMLU HASTALARIN BAŞVURU ÖZELLİKLERİ, TEDAVİ VE TAKİP SONUÇLARI

Bahadır KÜLAH
Derya ÇAYIR
MEHMET BOZKURT
Pages
120–126
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Thyroidectomy specimens of all patients were reported as DTC, Preoperatively only in 44 (24%) patients were reported as malign or suspicion of malignancy according to the results of FNAC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Postoperative radioactive iodine (RAI) ablation is one of the options for complementary treatment after thyroidectomy of differentiated thyroid carcinoma (DTC).
📊
Key Findings & Data:Patients and Methods: 187 (165 female, 22 male) patients, were reported as DTC and postoperative scintigraphy revealed residual thyroid tissue between January 2014 and July 2018, were enrolled in the study.
💡
Conclusion & Impact:Results: Thyroidectomy specimens of all patients were reported as DTC, Preoperatively only in 44 (24%) patients were reported as malign or suspicion of malignancy according to the results of FNAC.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Postoperative radioactive iodine (RAI) ablation is one of the options for complementary treatment after thyroidectomy of differentiated thyroid carcinoma (DTC). The evaluation of the residual tissue after thyroidectomy is important for the effectiveness of RAI ablation. In our study, we evaluate the presentation and outcomes of the patients with residual thyroid tissue and aimed to identify the risk factors related with the presence of the residual thyroid tissue. Patients and Methods: 187 (165 female, 22 male) patients, were reported as DTC and postoperative scintigraphy revealed residual thyroid tissue between January 2014 and July 2018, were enrolled in the study. The parameters including age, gender, ultrasonography findings, fine needle aspiration cytology (FNAC) reports, type of the surgery, tumour diameter, multifocality, postoperative serum thyroglobulin (Tg) levels, thyroid scintigraphy, RAI ablation, and locoregional recurrence were compared by Mann Whitney-U, Kruskal Wallis, and qi-square test in SPSS 18.0 for Windows software. P value is accepted as significant if below 0.05. Results: Thyroidectomy specimens of all patients were reported as DTC, Preoperatively only in 44 (24%) patients were reported as malign or suspicion of malignancy according to the results of FNAC. Papillary thyroid microcarcinoma (PTMC) was significantly more common in the group of patients older than 45 (p

Özet

Amaç: Postoperatif radyoaktif iyot (RAI) ablasyonu, diferansiye tiroid karsinomlarında (DTK) tiroidektomi sonrası ta-mamlayıcı tedavi seçeneklerinden birisidir. Tiroidektomi sonrası rezidü dokunun değerlendirilmesi, postoperatif RAIablasyonunun etkinliği açısından önemlidir. Çalışmamızda total tiroidektomi (TT) sonrası rezidü doku tespit edilmişDTK’lı olgularda başvuru özellikleri, tedavi ve takip sonuçlarını retrospektif olarak inceledik.Hastalar ve Metod: Ocak 2014-Temmuz 2018 tarihleri arasında tiroidektomi sonrası patoloji sonucu DTK olarakraporlanan, postoperatif sintigrafide rezidü tiroid dokusu tespit edilmiş 187 (165 kadın, 22 erkek) hasta çalışmayadahil edildi. Yaş, cinsiyet, ultrasonografi bulguları, ince iğne aspirasyon biyopsi (İİAB) sonuçları, yapılan cerrahi giri-şimin tipi, tümör çapı, multifokalite, postoperatif serum tiroglobulin (Tg) düzeyi, tiroid sintigrafisi, RAI ablasyonu velokorejyonel rekürrens gibi parametreler Windows için SPSS 18.0 programı ile Mann Whitney-U, Kruskal Wallis veki-kare testleri kullanılarak değerlendirildi. P değeri < 0,05 ise anlamlı kabul edildi.Bulgular: Tüm hastaların tiroidektomi spesimenlerinin histopatolojik değerlendirme sonucu DTK iken, ameliyat ön-cesi sadece 44’ünde (%24) İİAB sonucu malign ya da malignite şüphesi olarak raporlanmıştı. 45 yaşından büyükhasta grubunda papiller tiroid mikrokarsinomu (PTMK) anlamlı olarak daha sık gözlendi (p

🔖

Cite This Article

KÜLAH, B., ÇAYIR, D., BOZKURT, M. (2022). Presentations and Outcomes of Patients with Residual Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma. Bozok Tıp Dergisi, Cilt: 9 - Sayı: 2, 120–126. https://ajindex.com/articles/468623

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Kaliszewski K, Zubkiewicz-Kucharska A, Kiełb P, Maksymow- icz J, Krawczyk A, Krawiec O. Comparison of the prevalence of incidental and non-incidental papillary thyroid microcarcinoma during 2008-2016: a single-center experience. World J Surg Oncol. 2018;16(1):202. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klop- per JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocri- nol Metab. 2009;94(6):2092-8.
  2. Ertorer ME, Tutuncu NB, Ozyilkan O. Incidental papillary micro- carcinoma of the thyroid. Asian Pac J Cancer Prev. 2007;8(4):631-4.
  3. Kaliszewski K, Wojtczak B, Strutyńska-Karpińska M, Łukieńczuk T, Forkasiewicz Z, Domosławski P. Incidental and non-incidental thyroid microcarcinoma. Oncol Lett. 2016;12(1):734-40.
  4. Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey TJ 3rd. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid. 2009 May;19(5):473-7. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
  5. Khammash NF, Halkar RK, Abdel-Dayem HM. The use of technetium-99m pertechnetate in postoperative thyroid carcinoma. A comparative study with iodine-131. Clin Nucl Med. 1988;13(1):17-22.
  6. Ozdemir D, Cuhaci FN, Ozdemir E, Aydin C, Ersoy R, Turkolmez S, et al. The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer. Nucl Med Commun. 2016;37(6):640-5.
  7. Ha S, Oh SW, Kim YK, Koo do H, Jung YH, Yi KH, et al. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer. J Korean Med Sci. 2015;30(7):876-81. Rosario PW, dos Santos JB, Calsolari MR. Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study. Horm Metab Res. 2013;45(12):911-4.
  8. Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Cross G. Bio- chemical persistence in thyroid cancer: is there anything to worry about?